768,510 Shares in uniQure N.V. $QURE Bought by Fiera Capital Corp

Fiera Capital Corp acquired a new position in shares of uniQure N.V. (NASDAQ:QURE) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 768,510 shares of the biotechnology company’s stock, valued at approximately $18,390,000.

Other institutional investors have also made changes to their positions in the company. Torren Management LLC acquired a new stake in shares of uniQure during the fourth quarter worth $28,000. Jones Financial Companies Lllp lifted its holdings in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 509 shares in the last quarter. IFP Advisors Inc bought a new position in uniQure during the fourth quarter worth about $48,000. CIBC Private Wealth Group LLC bought a new position in uniQure during the third quarter worth about $50,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in uniQure by 42.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 906 shares in the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Jack Kaye sold 2,645 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $30.01, for a total transaction of $79,376.45. Following the sale, the director owned 20,439 shares in the company, valued at approximately $613,374.39. This represents a 11.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Walid Abi-Saab sold 45,000 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $25.06, for a total value of $1,127,700.00. Following the sale, the insider owned 169,669 shares in the company, valued at $4,251,905.14. The trade was a 20.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.65% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Wells Fargo & Company upgraded uniQure from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $15.00 to $60.00 in a report on Monday, March 9th. Chardan Capital lifted their target price on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. The Goldman Sachs Group lifted their target price on uniQure from $9.00 to $10.00 and gave the stock a “neutral” rating in a report on Monday, April 20th. Barclays reduced their target price on uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a report on Monday, March 23rd. Finally, Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Ten investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $42.83.

uniQure Stock Performance

Shares of uniQure stock opened at $27.00 on Tuesday. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of -7.76 and a beta of 0.98. The stock’s 50-day moving average is $21.62 and its 200-day moving average is $21.78. uniQure N.V. has a one year low of $8.73 and a one year high of $71.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. The company had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Equities analysts predict that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.